Newer clinically available antithrombotics and their antidotes

Area of Science:

• Pharmacology and Therapeutics
• Cardiology
• Hematology

Background:

• New oral anticoagulants (NOACs) are alternatives to warfarin for thromboembolism and stroke prevention in non-valvular atrial fibrillation (AF).
• Approved NOACs include dabigatran (direct thrombin inhibitor), rivaroxaban, and apixaban (direct factor Xa inhibitors).
• A key concern with NOACs is the absence of specific antidotes for managing emergencies like major bleeding or urgent surgery.

Purpose of the Study:

• To review the current status of specific antidotes for NOACs.
• To discuss the management of bleeding or surgical emergencies in patients on NOACs.
• To highlight the need for further research into effective reversal agents.

Main Methods:

• Literature review of randomized trials and clinical studies on NOACs.
• Examination of research on specific and non-specific reversal agents for dabigatran, rivaroxaban, and apixaban.
• Analysis of expert opinions and position papers on managing NOAC-related emergencies.

Main Results:

• Currently, no specific antidotes are approved for clinical use with the three main NOACs.
• Research is underway, with phase I/II studies for specific antidotes for dabigatran, rivaroxaban, and apixaban.
• Prothrombin complex concentrates (PCCs) and recombinant factor VII show promise in experimental studies for reversing NOAC effects.

Conclusions:

• Effective and specific reversal agents for NOACs are still under development.
• Management of bleeding or surgical emergencies currently relies on non-specific agents and expert opinion.
• Further clinical trials are needed to establish evidence-based guidelines for NOAC reversal.